TIDMOBD
RNS Number : 8712S
Oxford BioDynamics PLC
18 November 2021
18 November 2021
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received
notice that Vulpes Life Sciences Fund and Testudo Fund, which are
controlled by Non-Executive Director, Stephen Diggle, have
purchased 2,000,000 Ordinary Shares of 1 pence each ("shares") and
500,000 shares respectively, at a price of 45.5p per share.
Following this transaction, Vulpes Life Sciences Fund is
interested in 13,810,670 shares, representing 13.76% of the
Company's current issued share capital and Vulpes Testudo Fund is
interested in 932,204 shares, representing 0.93% of the Company's
current issued share capital. Through the holdings of Vulpes Life
Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested
in 14,742,874 shares, representing approximately 14.69% of the
Company's current issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Stephen Diggle
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- --------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
------------------------------- --------------------------------------
b) LEI 2138005Y1TK258O5U928
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.455 2,000,000
----------
0.455 500,000
----------
------------------------------- --------------------------------------
d) Aggregated information Price Volume
- Aggregated volume 0.455 2,500,000
- Price ----------
------------------------------- --------------------------------------
e) Dates of the transactions 16 November 2021
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
John More +44 (0)20 7408 4090
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Nathan OxfordBioDynamics@instinctif.com
Billis
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit . Its next product will be EpiSwitch(R) CiRT (Checkpoint
Inhibitor Response Test) for cancer, a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
to be launched later in 2021.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBPBATMTMBBTB
(END) Dow Jones Newswires
November 18, 2021 10:10 ET (15:10 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024